Clinical Trial Update: Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial of eculizumab for antibody-mediated rejection after kidney transplant was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection
• Humoral Rejection

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Antibody-mediated Rejection, Humoral Rejection | Phase 2 | Status: TERMINATED | Results posted: 2017-09-21